1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases.
Authors
Ou, S-HTiseo, M
Camidge, R
Ahn, M
Huber, R
Hochmair, M
Kim, S-W
West, H
Reckamp, K
Molina, J
Liu, G
Delmonte, A
Viteri, S
Bearz, A
Summers, Yvonne J
Reichmann, W
Kerstein, D
Gettinger, S
Kim, D-W
Affiliation
"Chao Family Comprehensive Cancer Center, University of California Irvine School ofIssue Date
2017-09
Metadata
Show full item recordCitation
1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx380.047Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx380.047/4109402/1345PIntracranial-efficacy-of-brigatinib-BRG-inType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx380.047